

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

Xilio Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

828 Winter Street, Suite 300
Waltham, Massachusetts
(Address of Principal Executive Offices)

85-1623397
(U.S. Employer
Identification No.)

02451
(Zip Code)

Third Amended and Restated 2022 Inducement Stock Incentive Plan
(Full Title of the Plan)

René Russo
President and Chief Executive Officer
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, Massachusetts 02451
(Name and Address of Agent for Service)

(857) 524-2466
(Telephone Number, Including Area Code, of Agent for Service)

Copy to:

Ben Harshbarger
Chief Legal Officer
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, Massachusetts 02451
(857) 524-2466

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐
Non-accelerated filer ☒

Accelerated filer ☐
Smaller reporting company ☒
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Statement of Incorporation by Reference

This Registration Statement on Form S-8, relating to the Third Amended and Restated 2022 Inducement Stock Incentive Plan (the "2022 Inducement Plan") of Xilio Therapeutics, Inc. (the "Registrant") is being filed for the purpose of registering 373,555 additional

securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8 (File No. 333-270240) filed with the Securities and Exchange Commission ("SEC") on [March 2, 2023](#) by the Registrant relating to the 2022 Inducement Plan, (ii) the Registration Statement on Form S-8 (File No. 333-285701) filed with the SEC on [March 11, 2025](#) by the Registrant relating to the 2022 Inducement Plan, and (iii) the Registration Statement on Form S-8 (File No. 333-294515) filed with the SEC on [March 23, 2026](#) by the Registrant relating to the 2022 Inducement Plan, except, in each case, to the extent amended or superseded by the contents hereof and for "Item 8. Exhibits" with respect to which the exhibit index set forth below is incorporated herein by reference.

Item 8. Exhibits.

The following exhibits are incorporated herein by reference:

Number	Description
4.1	Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 10-K (File No. 001-40925), filed with the Securities and Exchange Commission on March 23, 2026)
4.2	Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-40925), filed with the Securities and Exchange Commission on April 3, 2023)
5.1*	Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant
23.1*	Consent of Ernst & Young LLP, independent registered public accounting firm
23.2*	Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
24.1*	Power of attorney (included on the signature pages of this registration statement)
99.1	Third Amended and Restated 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant's Current Report on Form 10-Q (File 001-40925) filed with the Securities and Exchange Commission on August 12, 2026)
107*	Filing Fee Table

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts on this 12th day of August, 2026.

XILIO THERAPEUTICS, INC.

By: /s/ René Russo

René Russo

President and Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Xilio Therapeutics, Inc., hereby severally constitute and appoint René Russo and Ben Harshbarger, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Xilio Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
<u>/s/ René Russo</u> René Russo	President and Chief Executive Officer, Director <i>(Principal Executive Officer)</i>	August 12, 2026
<u>/s/ Christopher Frankenfield</u> Christopher Frankenfield	Chief Financial Officer and Chief Operating Officer <i>(Principal Financial and Accounting Officer)</i>	August 12, 2026
<u>/s/ Sara M. Bonstein</u> Sara M. Bonstein	Chair of the Board	August 12, 2026
<u>/s/ Akintunde Bello</u> Akintunde Bello	Director	August 12, 2026
<u>/s/ Cheryl R. Blanchard</u> Cheryl R. Blanchard	Director	August 12, 2026
<u>/s/ Aoife Brennan</u> Aoife Brennan	Director	August 12, 2026
<u>/s/ Daniel Curran</u> Daniel Curran	Director	August 12, 2026
<u>/s/ Robert Ross</u> Robert Ross	Director	August 12, 2026
<u>/s/ James Shannon</u> James Shannon	Director	August 12, 2026
<u>/s/ Yuan Xu</u> Yuan Xu	Director	August 12, 2026

August 12, 2026

Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, Massachusetts 02451

Re: Xilio Therapeutics, Inc. Third Amended and Restated 2022 Inducement Stock Incentive Plan

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 373,555 shares of common stock, \$0.0001 par value per share (the “Shares”), of Xilio Therapeutics, Inc., a Delaware corporation (the “Company”), issuable under the Company’s Third Amended and Restated 2022 Inducement Stock Incentive Plan (the “Plan”).

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement, the Plan and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plan, to register and qualify the Shares for sale under all applicable state securities or “blue sky” laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109

Berlin Boston Brussels Denver Frankfurt London Los Angeles New York Palo Alto San Francisco Washington

August 12, 2026
Page 2

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plan, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

/S/ WILMER CUTLER PICKERING HALE AND DORR LLP

WILMER CUTLER PICKERING HALE AND DORR LLP

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Third Amended and Restated 2022 Inducement Stock Incentive Plan of Xilio Therapeutics, Inc. of our report dated March 23, 2026, with respect to the consolidated financial statements of Xilio Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts
August 12, 2026

[illegible]